Ory Rouvio

756 total citations
19 papers, 126 citations indexed

About

Ory Rouvio is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ory Rouvio has authored 19 papers receiving a total of 126 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 9 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Ory Rouvio's work include Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Ory Rouvio is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Ory Rouvio collaborates with scholars based in Israel, United States and Italy. Ory Rouvio's co-authors include Tamar Tadmor, Moshe E. Gatt, Hila Magen, Yaël C. Cohen, Irit Avivi, Noa Lavi, Chezi Ganzel, Evgeni Chubar, Tzippy Shochat and Tatyana Dvorkin and has published in prestigious journals such as Blood, International Journal of Molecular Sciences and Vaccine.

In The Last Decade

Ory Rouvio

18 papers receiving 124 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ory Rouvio Israel 7 76 71 51 38 20 19 126
Camila Peña Chile 6 43 0.6× 54 0.8× 36 0.7× 26 0.7× 12 0.6× 43 111
Immacolata Attolico Italy 6 27 0.4× 82 1.2× 44 0.9× 47 1.2× 29 1.4× 17 146
Kenneth Nahum United States 6 53 0.7× 60 0.8× 42 0.8× 21 0.6× 8 0.4× 13 117
Shlomzion Aumann Israel 7 97 1.3× 53 0.7× 51 1.0× 33 0.9× 9 0.5× 25 160
Kalyan Nadiminti United States 6 65 0.9× 68 1.0× 24 0.5× 18 0.5× 19 0.9× 24 115
Pavlina Konstantinidou Greece 8 46 0.6× 110 1.5× 39 0.8× 56 1.5× 12 0.6× 12 124
Gabriela Borsaru Romania 7 105 1.4× 111 1.6× 38 0.7× 28 0.7× 5 0.3× 11 169
Shanisha Gordon-Mitchell United States 2 97 1.3× 98 1.4× 20 0.4× 33 0.9× 55 2.8× 5 165
Jorge Monge United States 7 68 0.9× 72 1.0× 46 0.9× 12 0.3× 14 0.7× 15 119
Dorotea Fantl Argentina 8 130 1.7× 132 1.9× 79 1.5× 23 0.6× 10 0.5× 33 201

Countries citing papers authored by Ory Rouvio

Since Specialization
Citations

This map shows the geographic impact of Ory Rouvio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ory Rouvio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ory Rouvio more than expected).

Fields of papers citing papers by Ory Rouvio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ory Rouvio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ory Rouvio. The network helps show where Ory Rouvio may publish in the future.

Co-authorship network of co-authors of Ory Rouvio

This figure shows the co-authorship network connecting the top 25 collaborators of Ory Rouvio. A scholar is included among the top collaborators of Ory Rouvio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ory Rouvio. Ory Rouvio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ganzel, Chezi, Svetlana Trestman, Shai Levi, et al.. (2022). Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group. Leukemia & lymphoma. 63(14). 3448–3455. 1 indexed citations
2.
Iraqi, Muhammed, Avishay Edri, Yariv Greenshpan, et al.. (2022). Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma. International Journal of Molecular Sciences. 23(9). 4717–4717. 10 indexed citations
3.
Gatt, Moshe E., Iuliana Vaxman, Tamar Tadmor, et al.. (2020). Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review. European Journal Of Haematology. 106(2). 184–195. 18 indexed citations
4.
Cohen, Yaël C., Hila Magen, Noa Lavi, et al.. (2020). Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study. Annals of Hematology. 99(6). 1273–1281. 13 indexed citations
5.
Luttwak, Efrat, Moshe E. Gatt, Noa Lavi, et al.. (2020). Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study. Clinical Lymphoma Myeloma & Leukemia. 20(11). e850–e857. 1 indexed citations
6.
Levi, Itai, Ohad Etzion, Alexander Fich, et al.. (2020). Incidence rates and clinical characteristics of primary gastrointestinal non-Hodgkin lymphoma: a population study. European Journal of Gastroenterology & Hepatology. 32(5). 569–574. 2 indexed citations
7.
Tadmor, Tamar, Ilana Levy, Yair Herishanu, et al.. (2019). Primary peg-filgrastim prophylaxis versus filgrastim given “on demand” for neutropenia during therapy with cladribine for hairy cell leukemia. Leukemia Research. 82. 24–28. 2 indexed citations
8.
9.
Ganzel, Chezi, Ory Rouvio, Irit Avivi, et al.. (2018). Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome. Leukemia Research. 68. 9–14. 10 indexed citations
10.
Ohana, Nissim, et al.. (2018). Classification of Solitary Plasmacytoma, Is it more Intricate than Presently Suggested? A Commentary. Journal of Cancer. 9(21). 3894–3897. 6 indexed citations
11.
Herishanu, Yair, Neta Goldschmidt, Osnat Bairey, et al.. (2018). Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel. Anticancer Research. 38(11). 6423–6429. 8 indexed citations
12.
Cohen, Yaël C., Hila Magen, Noa Lavi, et al.. (2018). Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study. Blood. 132(Supplement 1). 1972–1972. 1 indexed citations
13.
Benharroch, Daniel, et al.. (2017). Composite Nasopharyngeal plasmacytoma with nodal paraimmunoblastic variant of small lymphocytic lymphoma: A case report. Oncology Letters. 14(2). 1745–1747. 1 indexed citations
14.
Ganzel, Chezi, Ory Rouvio, Hila Magen, et al.. (2016). Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. Blood. 128(22). 5699–5699. 1 indexed citations
15.
Benjamini, Ohad, David Lavie, Eldad J. Dann, et al.. (2016). Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma. Blood. 128(22). 3008–3008. 3 indexed citations
16.
Ostfeld, Ishay, et al.. (2015). Primary gastric lymphoma in a soldier presenting as acute gastrointestinal bleeding. PubMed. 1(1). 4–4. 1 indexed citations
17.
Muchtar, Eli, Moshe E. Gatt, Ory Rouvio, et al.. (2015). Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. British Journal of Haematology. 172(1). 89–96. 31 indexed citations
18.
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Camila Peña Breakdown of academic impact, for papers by Immacolata Attolico Breakdown of academic impact, for papers by Kenneth Nahum Breakdown of academic impact, for papers by Shlomzion Aumann Breakdown of academic impact, for papers by Kalyan Nadiminti Breakdown of academic impact, for papers by Pavlina Konstantinidou Breakdown of academic impact, for papers by Gabriela Borsaru Breakdown of academic impact, for papers by Shanisha Gordon-Mitchell Breakdown of academic impact, for papers by Jorge Monge Breakdown of academic impact, for papers by Dorotea Fantl
Rankless by CCL
2026